Development of RP-HPLC Method for Simultaneous Determination of Bilastine and Montelukast by Qbd Approach and Its Validation
Pharmaceutical Science-Pharmaceutical Analysis
DOI:
https://doi.org/10.22376/ijlpr.2023.13.5.P241-P255Keywords:
Bilastine, Montelukast sodium, RP-HPLC,, UV-Spectroscopy, QbD, validation.Abstract
This study proposes to develop and validate the RP-HPLC method for Bilastine (BIL) and Montelukast (MKT) byQbD to substantiate the RP-HPLC analysis as per ICH validation guidelines. Quality by Design (QbD) allows the accomplishmentof specific unsurprising quality with a predetermined and wanted determination. The simultaneous estimation of BIL and MKTwas performed with C18 (4.6×250 mm, 5-μm particle size) with an LC-10AD pump and PDA detector. The mobile phaseemployed methanol and ammonium acetate buffer pH-3.6 at 85:15 v/v. The flow rate was maintained at 1.0 ml/min, and BIL andMKT were detected at 249nm and 293 nm by UV detector, respectively. The HPLC method provided linear responses found inthe 200–600 μg/ml range. The correlation coefficient was 0.9995 for BIL and 0.9991 for MKT. The LOD and LOQ for BIL andMKT were found to be 0.493, 1.495 μg/ml, and 0.693, 2.100, respectively. The percentage recovery for BIL was 95.33 to 102.06,and for MKT was 96.31 to 104.05, respectively. Calculated information acquired for both the preliminaries roughly coordinateswith the information given by Design expert programming, showing the chromatographic condition's genuineness. Design-Expertversion 10 ("DX10") software has calculated this calculation, setting a composite design of significant parameters. A newselective, rapid, accurate, precise, and sensitive RP-HPLC method was developed and evaluated for the simultaneousdetermination of Bilastine (BIL) and Montelukast sodium (MKT) in a bulk and pharmaceutical dosage form. This method is usefulin the routine quality analysis of combinations of BIL and MKT in bulk and its tablet formulations.
References
Drug profile for Bilastine; November 2020. Available on.[cited on Jul 30, 2022]. Available from: https://go.drugbank.com/drugs/DB11591.
Indian pharmacopoeia. 7th ed, The Indian Pharmacopeia commission. Vol. II. Government of India, Ministry of Health and Family Welfare. Ghaziabad; 2018. p. 2628-9.
British pharmacopeia commission. British pharmacopoeia: Volume III. London: TSO; 2015, 311-2.
Drug profile for Montelukast; November 2020. [cited on Jul 30, 2022]. Available from: https://go.drugbank.com/drugs/DB00471.
Singular (montelukast sodium) US FDA Label; 2019. Available on [cited on Jul 30, 2022]. Available from: https://www.merck.com/product/usa/pi_circulars/s/singulair/singulair_pi.pdf.
Apo-montelukast Canadian product monograph.
Electronic medicine compendium: montelukast 10 mg film-coated tablets Monograph. Available on.[cited on Jul 30, 2022]. Available from: https://www.medicines.org.uk/emc/product/1243/smpc.
Lu CY, Zhang F, Lakoma MD, Butler MG, Fung V, Larkin EK et al. Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors. Clin Ther. 2015 janvier 1;37(6):1280-91. doi: 10.1016/j.clinthera.2015.03.027, PMID 25920571.
Amrendra Chowdary V. Anusha Kota and s. Muneer. Method development and validation of new RP-HPLC method for the estimation of Bilastine in a pharmaceutical dosage form. World J Pharm Pharm Sci. July 2017;6(8):2297-315.
Tassinari da Silva A, Rossi Brabo G, Dias Marques I, Bajerski L, Donadel Malesuik M, Soldateli Paim C. UV spectrophotometric method for the quantitative determination of Bilastine using experimental design for robustness. Drug Anal Res. 2017;1(2):38-43. doi: 10.22456/2527-2616.79221.
PeethalaPrathyusa RS. UV spectrophotometric method for determination of Bilastine in bulk and pharmaceutical formulation. Res J Pharm Technol. 2020;13(2):1-17.
Firdous S, Rizwan SH. Analytical method development and validation for calculating Bilastine in bulk and pharmaceutical dosage form by HPLC. World J Pharm Life Sci. 2020;6(10):138-43.
Terzic J, Popović I, Stajić A, Tumpa A, Jančić-Stojanović B, Igor Popavic, AnjaTumpa, et al. Application of Analytical Quality by Design concept for bilastine and its degradation impurities determination by hydrophilic interaction liquid chromatographic method. J Pharm Biomed Anal. 2016;125:385-93. doi: 10.1016/j.jpba.2016.04.022, PMID 27131148.
Reid GL, Morgado J, Barnett K, Harrington B, Wang J, Harwood J. Analytical quality by design (AQbD) in pharmaceutical development. Am Pharm Rev. 2013;16(5).
Rozet E, Ziemons E, Marini RD, Boulanger B, Hubert P. Quality by design compliant analytical method validation. Anal Chem. 2012;84(1):106-12. doi: 10.1021/ac202664s, PMID 22107128.
International Conference on Harmonization, ICH Q2 (R1): Validation of Analytical Procedures. Geneva: text and methodology; 2005.
Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008;25(4):781-91. doi: 10.1007/s11095-007-9511-1, PMID 18185986.
Berry DA, Lewis GA, Mathieu D, Phan-Tan-Luu R. Pharmaceutical experimental design. J Am Stat Assoc. 2000;95(449):339. doi: 10.2307/2669571.
Sylvester B, Tefas L, Vlase L, Tomuţă I, Porfire A. A Quality by Design (QbD) approach to the development of a gradient high-performance liquid chromatography for the simultaneous assay of curcuminoids and doxorubicin from long-circulating liposomes. J Pharm Biomed Anal. 2018;158:395-404. doi: 10.1016/j.jpba.2018.06.018, PMID 29966945.
Tomba E, Facco P, Bezzo F, Barolo M. Latent variable modeling to assist the implementation of Quality-by-Design paradigms in pharmaceutical development and manufacturing: a review. Int J Pharm. 2013;457(1):283-97. doi: 10.1016/j.ijpharm.2013.08.074, PMID 24016743.
Andhale SM, Nikalje AP G. Simultaneous estimation of Bilastine and montelukast in bulk by RP-HPLC and assessment of its applicability in marketed tablet dosage form. J Pharm Res Int. 2022;34(3B):8-25:Article no. JPRI.79943. doi: 10.9734/jpri/2022/v34i3B35388.
PeethalaPrathyusa RS. UV spectrophotometric method for determination of Bilastine in bulk and pharmaceutical formulation. Res J Pharm Technol. 2020;13(2):1-17.
Ouarezki R, Guermouche S, Guermouche M-H. Degradation kinetics of Bilastine determined by RP-HPLC method and identification of its degradation product in oxidative condition. Institute of Chemistry, Slovak Academy of Sciences; 2019.
The Indian Pharmacopoeia-2018. 7th ed, The Indian Pharmacopeia commission. Vol. II. Government of India, Ministry of Health and Family Welfare. Ghaziabad; 2018. p. 2628-9.
da Silva AT, Brabo GR, Marques ID, Bajerski L, Malesuik MD, Paim CS. UV spectrophotometric method for quantitative determination of Bilastine using experimental design for robustness. Drug Analytical Research. 2017 Dec 28;1(2):38-43.
Pallavi K, Srinivasa Babu P. Validated UV spectroscopic method for estimation of montelukast sodium from bulk and tablet formulations. Int J Pharm Sci Res (IJPSR). 2012;1(2):104-11.
Singh K. Param Deep Bagga, Pragati Shakya, et al. Validated UV spectroscopic method for estimation of montelukast sodium. Int J Pharm Sci Res (IJPSR). 2015;6(11)(v):4728-32.
Prathyusa P, Sunderajan R. UV spectrophotometric method for determination of Bilastine in bulk and pharmaceutical formulation. Res J Pharm Technol. 2020;13(2):1-17.
Rana NS, Rajesh KS, Patel NN et al. Development of PR-HPLC method for simultaneous estimation of montelukast and ebastine in tablet dosage form. Int J Pharm Sci. July 2013;7(1):1-7.
Terzic J, Popović I, Stajić A, Tumpa A, Jančić-Stojanović B, Igor popavic. Application of Analytical Quality by Design concept for bilastine and its degradation impurities determination by hydrophilic interaction liquid chromatographic method. J Pharm Biomed Anal. 2016;125:385-93. doi: 10.1016/j.jpba.2016.04.022, PMID 27131148.
Vekaria H, Limbasiya V, Patel P. Development and validation of RP-HPLC method for simultaneous estimation of montelukast sodium and fexofenadine hydrochloride in the combined dosage form. J Pharm Res Sciverse Sci Direct. 2013;2013; 6:134-9.
Amaresha S, Jhat Rakesh K. RP-UPLC method development and validation for the simultaneous estimation of montelukast and ebastine in bulk and pharmaceutical dosage form. Int J Pharm Anal Res. 2018;7(1):96-105. aa.
Radhakrishna T, Narasaraju A, Ramakrishna M, Satyanarayana A. Simultaneous determination of montelukast and loratidine by HPLC and derivative spectrophotometer methods. J Pharm Biomed Anal. 2003;31(2):359-68. doi: 10.1016/s0731-7085(02)00650-7, PMID 12609675.
Sowjanya G, Trideva Sastri K. UV spectrophotometric method development and validation for simultaneous determination of fexofenadine hydrochloride and montelukast sodium in tablets. World J Pharm Pharm Sci. 2017;6(10):780-9.
Mohan GB, Lakshmana RA, Venkateswara RJ. Method development and validation for simultaneous estimation of montelukast sodium and desloratadine by RP-HPLC. Int J Anal Chem. 2015;6:651-8.
Revathi R, Ethiraj T, Thenmozhi P, Saravanan VS, Ganesan V. High performance liquid chromatographic method development for simultaneous analysis of doxofylline and montelukast sodium in a combined form. Pharm Methods. 2011;2(4):223-8. doi: 10.4103/2229-4708.93390, PMID 23781461.
Raman NVVSS, Mallu UR, Bapatu HR. Analytical quality by design approach to test method development and validation in drug substance manufacturing. J Chem. 2015;2015:Article ID 435129, 8 pages. doi: 10.1155/2015/435129.
Stalikas C, Fiamegos Y, Sakkas V, Albanis T. Developments on chemometric approaches to optimize and evaluate microextraction. J Chromatogr A. 2009;1216(2):175-89. doi: 10.1016/j.chroma.2008.11.060, PMID 19084231.
Revathi R, Ethiraj T, Thenmozhi P, Saravanan VS, Ganesan V. High performance liquid chromatographic method development for simultaneous analysis of doxofylline and montelukast sodium in a combined form. Pharm Methods. 2011;2(4):223-8. doi: 10.4103/2229-4708.93390, PMID 23781461.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Aejaz Ahmed, Manjra Mehfuza U, Lajporiya Mubina, Sayyed Nazifa, Patel Seema, G.J. Khan, Qazi Majaz Ahamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.